Similarly, a previous GWAS revealed that two other CDH4 variants (rs1122269 and rs4925193) were associated with significant trends (although not at the level of the current study) in modifying the OS outcomes of patients receiving gemcitabine treatment for pancreatic cancer (Li et al., 2016). This evidence concerns the gene CDH4 and pancreatic neoplasm.